Tsuyoshi Fukuda

Summary

Affiliation: Cincinnati Children's Hospital Medical Center
Country: USA

Publications

  1. ncbi UGT1A9, UGT2B7, and MRP2 genotypes can predict mycophenolic acid pharmacokinetic variability in pediatric kidney transplant recipients
    Tsuyoshi Fukuda
    Division of Clinical Pharmacology, Cincinnati Children s Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio 45229 3039, USA
    Ther Drug Monit 34:671-9. 2012
  2. ncbi Nonsteroidal anti-inflammatory drugs may reduce enterohepatic recirculation of mycophenolic acid in patients with childhood-onset systemic lupus erythematosus
    Tsuyoshi Fukuda
    Division of Clinical Pharmacology and Pediatric Pharmacology Research Unit, Cincinnati Children s Hospital Medical Center, Cincinnati, Ohio 45229 3039, USA
    Ther Drug Monit 33:658-62. 2011
  3. ncbi Inosine monophosphate dehydrogenase (IMPDH) activity as a pharmacodynamic biomarker of mycophenolic acid effects in pediatric kidney transplant recipients
    Tsuyoshi Fukuda
    Division of Clinical Pharmacology and Pediatric Pharmacology Research Unit, Cincinnati Children s Hospital Medical Center, Cincinnati, Ohio, USA
    J Clin Pharmacol 51:309-20. 2011
  4. ncbi Development of population PK model with enterohepatic circulation for mycophenolic acid in patients with childhood-onset systemic lupus erythematosus
    Catherine M T Sherwin
    Division of Clinical Pharmacology, Cincinnati Children s Hospital Medical Center, Cincinnati, Ohio 45229 3039, USA
    Br J Clin Pharmacol 73:727-40. 2012
  5. ncbi Pharmacokinetics and pharmacodynamics of mycophenolic acid and their relation to response to therapy of childhood-onset systemic lupus erythematosus
    Anna Carmela P Sagcal-Gironella
    Division of Rheumatology, Cincinnati Children s Hospital Medical Center, Cincinnati, OH 45229 3039, USA
    Semin Arthritis Rheum 40:307-13. 2011
  6. ncbi Risk of tacrolimus toxicity in CYP3A5 nonexpressors treated with intravenous nicardipine after kidney transplantation
    David K Hooper
    Division of Nephrology and Hypertension, Cincinnati Children s Hospital Medical Center, Cincinnati, OH, USA
    Transplantation 93:806-12. 2012
  7. ncbi The evolution of population pharmacokinetic models to describe the enterohepatic recycling of mycophenolic acid in solid organ transplantation and autoimmune disease
    Catherine M T Sherwin
    Division of Clinical Pharmacology, Cincinnati Childrens Hospital Medical Center, Cincinnati, Ohio 45229 3039, USA
    Clin Pharmacokinet 50:1-24. 2011
  8. ncbi Morphine clearance in children: does race or genetics matter?
    Senthilkumar Sadhasivam
    Department of Anesthesia, Cincinnati Children s Hospital Medical Center, Cincinnati, Ohio, USA
    J Opioid Manag 8:217-26. 2012

Collaborators

Detail Information

Publications8

  1. ncbi UGT1A9, UGT2B7, and MRP2 genotypes can predict mycophenolic acid pharmacokinetic variability in pediatric kidney transplant recipients
    Tsuyoshi Fukuda
    Division of Clinical Pharmacology, Cincinnati Children s Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio 45229 3039, USA
    Ther Drug Monit 34:671-9. 2012
    ..Here, the combined contribution of these genetic variants to MPA pharmacokinetic variability was investigated in pediatric renal transplant recipients who were on mycophenolic mofetil maintenance therapy...
  2. ncbi Nonsteroidal anti-inflammatory drugs may reduce enterohepatic recirculation of mycophenolic acid in patients with childhood-onset systemic lupus erythematosus
    Tsuyoshi Fukuda
    Division of Clinical Pharmacology and Pediatric Pharmacology Research Unit, Cincinnati Children s Hospital Medical Center, Cincinnati, Ohio 45229 3039, USA
    Ther Drug Monit 33:658-62. 2011
    ..Here, we evaluated the effects of this potential drug-transporter interaction on MPA-PK in a cohort of patients with childhood-onset systemic lupus erythematosus on mycophenolate mofetil therapy...
  3. ncbi Inosine monophosphate dehydrogenase (IMPDH) activity as a pharmacodynamic biomarker of mycophenolic acid effects in pediatric kidney transplant recipients
    Tsuyoshi Fukuda
    Division of Clinical Pharmacology and Pediatric Pharmacology Research Unit, Cincinnati Children s Hospital Medical Center, Cincinnati, Ohio, USA
    J Clin Pharmacol 51:309-20. 2011
    ..Because IMPDH inhibition is well correlated to MPA concentration, pretransplant IMPDH activity may serve as an early marker to guide the initial level of MPA exposure required in a pediatric population...
  4. ncbi Development of population PK model with enterohepatic circulation for mycophenolic acid in patients with childhood-onset systemic lupus erythematosus
    Catherine M T Sherwin
    Division of Clinical Pharmacology, Cincinnati Children s Hospital Medical Center, Cincinnati, Ohio 45229 3039, USA
    Br J Clin Pharmacol 73:727-40. 2012
    ..This study aimed to develop a population pharmacokinetic (PK) enterohepatic recycling model for MPA in patients with childhood-onset systemic lupus erythematosus (cSLE)...
  5. ncbi Pharmacokinetics and pharmacodynamics of mycophenolic acid and their relation to response to therapy of childhood-onset systemic lupus erythematosus
    Anna Carmela P Sagcal-Gironella
    Division of Rheumatology, Cincinnati Children s Hospital Medical Center, Cincinnati, OH 45229 3039, USA
    Semin Arthritis Rheum 40:307-13. 2011
    ..The objectives of this study were to (1) characterize the pharmacokinetics (MPA-PK) and pharmacodynamics (MPA-PD) of MPA and (2) explore the relationship between MPA-PK and cSLE disease activity...
  6. ncbi Risk of tacrolimus toxicity in CYP3A5 nonexpressors treated with intravenous nicardipine after kidney transplantation
    David K Hooper
    Division of Nephrology and Hypertension, Cincinnati Children s Hospital Medical Center, Cincinnati, OH, USA
    Transplantation 93:806-12. 2012
    ....
  7. ncbi The evolution of population pharmacokinetic models to describe the enterohepatic recycling of mycophenolic acid in solid organ transplantation and autoimmune disease
    Catherine M T Sherwin
    Division of Clinical Pharmacology, Cincinnati Childrens Hospital Medical Center, Cincinnati, Ohio 45229 3039, USA
    Clin Pharmacokinet 50:1-24. 2011
    ..Already published population pharmacokinetic models will be examined, and the evolution of these models away from empirical approaches to more mechanism-based models will be discussed...
  8. ncbi Morphine clearance in children: does race or genetics matter?
    Senthilkumar Sadhasivam
    Department of Anesthesia, Cincinnati Children s Hospital Medical Center, Cincinnati, Ohio, USA
    J Opioid Manag 8:217-26. 2012
    ....